Effects of Coenzyme Q10 in PSP and CBD

Completed · Phase 2/Phase 3

Conditions studied: Progressive Supranuclear Palsy, Neurological Disorders

In brief

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

Key facts

Study ID

NCT00532571

Run by

Lahey Clinic

Starts

2004-01-01

Expected to finish

2005-09-01

Last updated by the study team

2018-06-15

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years
• Age > 40
• Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit.
• Patients agreeable to participate in the study.

You may not qualify if…

• Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.
• Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.
• History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
• Previous use of coenzyme Q10 within 60 days of the baseline visit.

Where it is running

• Lahey Clinic — Burlington, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.